Pancreatic cancer is a very aggressive type of cancer and is often called the "king of cancers." It is expected to become the second leading cause of cancer-related deaths by 2030 in the US. In many cases, people with pancreatic cancer have a change in their KRAS gene. This gene change, or mutation, happens in about 90% of those with this cancer. Traditional treatments like chemotherapy often don't work well and have many side effects. However, new treatments called targeted therapies, which specifically focus on the KRAS mutations, are being developed and tested.

This study aims to create a group of patients with KRAS-mutant pancreatic cancer to see how these new treatments work. It involves creating a database to collect information from patients in real-world settings and tracking their progress. This will help doctors understand which treatments work best.

• Participants will be part of a database study that collects information from various hospitals.
• There are no restrictions on age or gender for participation.
• Participants must agree to follow the study schedule and sign a consent form.